Cytek Biosciences (NASDAQ:CTKB) Shares Down 3% Following Insider Selling
Cytek Biosciences (NASDAQ:CTKB) Shares Down 3% Following Insider Selling
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating)'s stock price was down 3% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $10.32 and last traded at $10.48. Approximately 826 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 792,675 shares. The stock had previously closed at $10.80.
賽特克生物科技股份有限公司(納斯達克代碼：CTKB-GET Rating)週三股價下跌3%，此前一名內部人士拋售了該公司股票。該公司股價最低跌至10.32美元，最新報10.48美元。午盤交易中，約有826股股票易手，較792,675股的日均成交量下跌100%。該股此前收盤報10.80美元。
Specifically, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $15.16, for a total transaction of $53,060.00. Following the completion of the sale, the chief financial officer now owns 85,563 shares of the company's stock, valued at approximately $1,297,135.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CTO Ming Yan sold 20,000 shares of Cytek Biosciences stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $14.42, for a total transaction of $288,400.00. Following the sale, the chief technology officer now directly owns 8,005,624 shares in the company, valued at approximately $115,441,098.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock in a transaction on Monday, October 24th. The stock was sold at an average price of $15.16, for a total value of $53,060.00. Following the sale, the chief financial officer now owns 85,563 shares in the company, valued at $1,297,135.08. The disclosure for this sale can be found here. Insiders sold a total of 146,500 shares of company stock valued at $1,907,145 in the last quarter. 15.90% of the stock is currently owned by company insiders.
具體來説，首席財務官Patrik Jeanmonod在10月24日星期一的一次交易中出售了3500股該公司的股票。這些股票以15.16美元的平均價格出售，總成交額為53,060.00美元。出售完成後，首席財務官現在擁有該公司85563股股票，價值約1297135.08美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過這個環節。其他消息，CTO嚴明在10月19日星期三的一次交易中出售了20,000股Cytek Biosciences股票。該股以14.42美元的平均價格出售，總成交金額為288,400.00美元。出售後，首席技術官現在直接擁有該公司8,005,624股，價值約115,441,098.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在美國證券交易委員會網站。此外，首席財務官Patrik Jeanmonod在10月24日(星期一)的一次交易中出售了3500股Cytek Biosciences股票。股票以15.16美元的平均價格出售，總價值為53,060.00美元。出售後，首席財務官現在擁有該公司85,563股，價值1,297,135.08美元。關於這次銷售的披露可以找到這裏。上個季度，內部人士總共出售了146,500股公司股票，價值1,907,145美元。15.90%的股份目前由公司內部人士持有。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Piper Sandler lifted their target price on Cytek Biosciences from $16.00 to $18.00 in a report on Monday, November 14th.
另外，派珀·桑德勒在11月14日週一的一份報告中將Cytek Biosciences的目標價從16.00美元上調至18.00美元。
Cytek Biosciences Stock Down 0.2 %
Cytek Biosciences股價下跌0.2%
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). Cytek Biosciences had a negative net margin of 0.47% and a positive return on equity of 0.94%. The company had revenue of $40.48 million during the quarter, compared to the consensus estimate of $43.36 million. As a group, sell-side analysts forecast that Cytek Biosciences, Inc. will post 0.04 earnings per share for the current fiscal year.
賽特克生物科學公司(納斯達克代碼：CTKB-GET Rating)上一次公佈季度收益數據是在11月9日星期三。該公司公佈本季度每股收益為0.01美元，低於普遍預期的0.02美元(0.01美元)。Cytek Biosciences的淨利潤率為負0.47%，股本回報率為0.94%。該公司本季度營收為4,048萬美元，而普遍預期為4,336萬美元。賣方分析師預計，Cytek Biosciences，Inc.本財年的每股收益將為0.04美元。
Institutional Trading of Cytek Biosciences
賽特克生物科學的制度性交易
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in shares of Cytek Biosciences by 20.1% during the third quarter. Bank of New York Mellon Corp now owns 394,034 shares of the company's stock valued at $5,800,000 after acquiring an additional 66,045 shares in the last quarter. Advisory Research Inc. bought a new position in shares of Cytek Biosciences during the third quarter valued at approximately $614,000. State Street Corp raised its holdings in shares of Cytek Biosciences by 17.6% during the third quarter. State Street Corp now owns 2,030,253 shares of the company's stock valued at $29,885,000 after acquiring an additional 304,433 shares in the last quarter. Algert Global LLC raised its holdings in shares of Cytek Biosciences by 116.5% during the third quarter. Algert Global LLC now owns 46,055 shares of the company's stock valued at $678,000 after acquiring an additional 24,785 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Cytek Biosciences by 9.2% during the third quarter. UBS Asset Management Americas Inc. now owns 69,822 shares of the company's stock valued at $1,028,000 after acquiring an additional 5,865 shares in the last quarter. Institutional investors own 49.48% of the company's stock.
幾家對衝基金和其他機構投資者最近買賣了該股的股票。紐約梅隆銀行(Bank Of New York Mellon Corp)第三季度增持Cytek Biosciences股票20.1%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有394,034股該公司股票，價值5,800,000美元，此前該公司在上一季度增持了66,045股。諮詢研究公司在第三季度購買了價值約614,000美元的Cytek Biosciences股票的新頭寸。道富集團在第三季度增持了Cytek Biosciences的股票17.6%。道富銀行目前持有該公司2,030,253股股票，價值29,885,000美元，上一季度又收購了304,433股。阿爾蓋特全球有限責任公司在第三季度將其持有的賽特克生物科學公司的股票增加了116.5%。Alert Global LLC在上個季度增持了24,785股後，現在擁有46,055股該公司股票，價值678,000美元。最後，瑞銀資產管理美洲公司(UBS Asset Management America Inc.)在第三季度將其持有的Cytek Biosciences股票增加了9.2%。瑞銀資產管理美洲公司(UBS Asset Management America Inc.)目前持有69,822股該公司股票，價值1,028,000美元，此前該公司在上個季度增持了5,865股。機構投資者持有該公司49.48%的股份。
About Cytek Biosciences
關於賽特克生物科學公司
(Get Rating)
(獲取評級)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家細胞分析解決方案公司，提供細胞分析工具，促進生物醫學研究和臨牀應用的科學進步。它提供極光和北極光系統，這是一種光譜流動細胞儀，通過利用來自多個激光的熒光信號來區分單個細胞上的熒光標記來提供細胞分析；以及極光細胞分選系統，它利用全光譜圖譜技術進一步拓寬了細胞分析的潛在應用。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
- 免費獲取StockNews.com關於Cytek生物科學的研究報告(CTKB)
- 好時為什麼是一隻甜蜜的衰退股票
- 亞馬遜股票是否會在2023年為投資者提供服務？
- 分析師將貨運情緒轉回遠期
- 各機構預訂波音航班
- 兩家生物技術公司在其流水線中以單一產品掀起波瀾
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cytek Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。